Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.60 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.60 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.60 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.60 |
| ▸ | P2RY2 | P41231 | 12/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.50 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.49 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846581 | 0.89 | SLC28A1 (0.63) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL10782234 | 0.88 | SLC28A1 (0.59) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4950152 | 0.88 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1696779 | 0.88 | SLC28A1 (0.61) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL23710653 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL1585708 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL800228 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL21275617 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL566228 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 | |
| SCHEMBL4280246 | 0.86 | SLC28A1 (0.60) | SLC28A1SLC28A2SLC29A1SLC28A3P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105051194-A | Inhibitory oligonucleotides and their use in therapy | SAREPTA THERAPEUTICS INC | 2015-11-11 | — | — | CN | claimed |
| US-7883891-B2 | Using 5-bromo-deoxyuridine to identify actively dividing cells, separating and recovering cells using flow cytometry; diagnosing cell proliferation and aging disorders | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2011-02-08 | — | — | US | claimed |
| EP-1429812-A4 | UNIQUE PROPERTIES OF STEM CELLS | MASSACHUSETTS INST TECHNOLOGY (US) | 2006-04-26 | — | — | EP | claimed |
| US-20050074874-A1 | Unique properties of a stem cells | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2005-04-07 | — | — | US | claimed |
| EP-1429812-A2 | UNIQUE PROPERTIES OF STEM CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2004-06-23 | — | — | EP | claimed |
| WO-2003029402-A2 | UNIQUE PROPERTIES OF STEM CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2003-04-10 | — | — | WO | claimed |
| US-12636374-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-12616744-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-20260061043-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOF | PFIZER (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260048112-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOF | PFIZER INC. (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260027195-A1 | IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES | PFIZER (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260014241-A1 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PFIZER (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250381259-A1 | Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof | PFIZER (US) | 2025-12-18 | — | — | US | disclosed |
| WO-1997000089-A1 | METHOD FOR RADIOISOTOPIC DETECTION AND LOCALIZATION OF INFLAMMATION IN A HOST | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-01-03 | — | — | WO | disclosed |
| WO-1996032841-A9 | NOVEL THERAPEUTIC BINDING MOLECULE COMPLEXES | — | 1996-12-27 | — | — | WO | disclosed |
| WO-1996032841-A1 | NOVEL THERAPEUTIC BINDING MOLECULE COMPLEXES | BURSTEIN LABORATORIES, INC. (US) | 1996-10-24 | — | — | WO | disclosed |
| WO-1996013522-A9 | COMPLEMENTARILY BONDED TWO- AND THREE-DIMENSIONAL SUPRAMOLECULAR STRUCTURES | — | 1996-09-12 | — | — | WO | disclosed |
| WO-1996013522-A1 | COMPLEMENTARILY BONDED TWO- AND THREE-DIMENSIONAL SUPRAMOLECULAR STRUCTURES | BURSTEIN LABORATORIES, INC. (US) | 1996-05-09 | — | — | WO | disclosed |
| EP-0569533-A1 | ARYL MACROCYCLIC COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 1993-11-18 | — | — | EP | disclosed |
| WO-1992012709-A1 | ARYL MACROCYCLIC COMPOSITIONS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048112-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOF | IL17A, NEU3, SIGLEC9 | SLC28A1 3126/4885SLC28A2 3050/4885SLC29A1 2181/4885 |
| US-20250381259-A1 | Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof | CD44, CD47, FUT5 | SLC28A1 1876/4885SLC28A2 1681/4885SLC29A1 1922/4885 |
| US-20260027195-A1 | IMMUNOGENIC COMPOSITIONS FOR USE IN PNEUMOCOCCAL VACCINES | IL17A, CD14, SPOUT1 | SLC28A1 1210/4885SLC28A2 1469/4885SLC29A1 1112/4885 |
| US-12616744-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | PSEN1, CD44, CD47 | SLC28A1 2596/4885SLC28A2 2626/4885SLC29A1 1796/4885 |
| US-20260014241-A1 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | SIGLEC9, CMBL, CHI3L2 | SLC28A1 2144/4885SLC28A2 1188/4885SLC29A1 1298/4885 |
| US-12636374-B2 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | CSGALNACT1, LY96, C5AR2 | SLC28A1 2949/4885SLC28A2 1392/4885SLC29A1 2742/4885 |
| US-20260061043-A1 | IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATED CAPSULAR SACCHARIDE ANTIGENS, KITS COMPRISING THE SAME AND USES THEREOF | IL17A, SIGLEC7, PSPH | SLC28A1 1942/4885SLC28A2 2183/4885SLC29A1 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.